News Release

PHILADELPHIA – As we bask in the summer heat, it is easy to take for granted that humans are also prepared for the cold of winter, with overcoats in the closet and home heating systems ready to be fired up as an added assurance against falling temperatures. Not all warm-blooded animals are this fortunate. Mice, for example, rely on a specialized organ between their shoulder blades to produce heat when confronted with cold temperatures. This organ is composed of special fat cells, called brown adipose tissue, or brown fat for short. This week in Nature, a team from the Perelman School of Medicine at the University of Pennsylvania detail a molecule that acts as a molecular pilot light required to turn on the brown fat furnace.

Brown fat burns sugar and fat to produce radiant heat in the body. Researchers have turned their attention to these cells because some of the sugar and fat they burn is stored in the body and might otherwise lead to increases in white fat, the form that increases in obesity. 

“To harness the fat-burning potential of brown fat we must better understand how the body burns fuel to stay warm and how this relates to the storage of excess fuel as white fat in obesity,” said senior author Mitchell Lazar, MD, PhD, director of the Institute for Diabetes, Obesity, and Metabolism (IDOM) and the Willard and Rhoda Ware Professor in Diabetes and Metabolic Diseases

In mice, the furnace relies on a molecule called uncoupling protein 1 (UCP1), which acts like a heating element. Mice without the UCP1 gene cannot survive even short exposures to near-freezing temperatures. The pilot-light-like molecule is called histone deacetylase 3 (HDAC3). Lazar, co-first author Matthew Emmett, an MD/PhD student in his lab, and their IDOM colleagues found that mice lacking HDAC3 in their brown fat were unable to turn on the UCP1 gene and were just as susceptible to the deleterious effects of cold as mice that did not have the gene.  The study showed that HDAC3 acts much like a pilot light on a gas furnace -- the HDAC3 pilot light is required to turn on the brown fat furnace even when the UCP1 gene is intact. 

HDAC3 functions on the epigenome, the molecular component of the cell nucleus that specifies which genes are expressed -- and just as importantly, which ones are not -- in different cells of the body. The Penn team analyzed and integrated massive datasets of DNA sequences, which facilitated the discovery of the mechanism by which HDAC3 acts as the brown fat pilot light. This bioinformatics portion of the study was performed by co-first author Hee-Woong Lim, PhD, an IDOM postdoctoral fellow, and research assistant professor Kyoungjae Won, PhD.

Studies in the last five years have confirmed that adult humans also have brown fat. Although it is not located between the shoulder blades as it is in rodents, it is also activated by cold temperatures, albeit not sufficiently enough to substitute for clothes and heaters. Brown fat in adult humans is more diffusely distributed, with concentrations of cells in visceral areas such as the carotid and mammary artieries, the heart and lung, and such other solid organs as the pancreas, kidney, and spleen. Subcutaneous brown fat depots can also be found in the vicinity of neck muscles, the clavicles, and abdominal wall. These studies have also shown that people with obesity have less brown fat than lean people. 

Since brown fat burns sugars and fats within the body, it may be possible to boost metabolism for weight loss and diabetes control by dialing up the brown fat thermostat. Surprisingly, however, the mice lacking HDAC3 in brown fat did not become obese.  Whatever the link, the new work from Penn suggests it will be critical to make sure that the brown fat pilot light and furnace functions are kept in good working order.

Co-authors are Jennifer Jager, Hannah J. Richter, Marine Adlanmerini, Lindsey C. Peed, Erika R. Briggs, David J. Steger, Carrie A. Sims, and Joseph A. Baur, all from Penn, as well as Tao Ma and Zachary Gerhart-Hines from the University of Copenhagen.

This work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (R37-DK43806) and the JPB Foundation. 

Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.

The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.

The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.

Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.

Share This Page: